Behavioral/Systems/Cognitive

Direct Control of Peripheral Lipid Deposition by CNS GLP-1 Receptor Signaling Is Mediated by the Sympathetic Nervous System and Blunted in Diet-Induced Obesity

Ruben Nogueiras,1,2,3 Diego Pérez-Tilve,1 Christelle Veyrat-Durebez,4 Donald A. Morgan,5 Luis Varela,2,3 William G. Haynes,3 James T. Patterson,6 Emmanuel Disse,1 Paul T. Pfluger,1 Miguel López,2,3 Stephen C. Woods,1 Richard DiMarchi,6 Carlos Diéguez,2,3 Kamal Rahmouni,3 Françoise Rohner-Jeannenaud,4 and Matthias H. Tschöp1,7

1Department of Psychiatry, Obesity Research Centre, University of Cincinnati, Cincinnati, Ohio 45226, 2Department of Physiology, University of Santiago de Compostela–Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain, 3Centro de Investigación Biomédica en Red (CIBERobn), Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 15782, Spain, 4Laboratory of Metabolism, Division of Endocrinology, Diabetology and Nutrition, Department of Internal Medicine, Faculty of Medicine, University of Geneva, Geneva 12114, Switzerland, 5Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242, 6Department of Chemistry, Indiana University, Bloomington, Indiana 47405, and 7Department of Pharmacology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthehl 14558, Germany

We investigated a possible role of the central glucagon-like peptide (GLP-1) receptor system as an essential brain circuit regulating adiposity through effects on nutrient partitioning and lipid metabolism independent from feeding behavior. Both lean and diet-induced obesity mice were used for our experiments. GLP-1 (7–36) amide was infused in the brain for 2 or 7 d. The expression of key enzymes involved in lipid metabolism was measured by real-time PCR or Western blot. To test the hypothesis that the sympathetic nervous system may be responsible for informing adipocytes about changes in CNS GLP-1 tone, we have performed direct recording of sympathetic nerve activity combined with experiments in genetically manipulated mice lacking β-adrenergic receptors. Intracerebroventricular infusion of GLP-1 in mice directly and potently decreases lipid storage in white adipose tissue. These effects are independent from nutrient intake. Such CNS control of adipocyte metabolism was found to depend partially on a functional sympathetic nervous system. Furthermore, the effects of CNS GLP-1 on adipocyte metabolism were blunted in diet-induced obese mice. The CNS GLP-1 system decreases fat storage via direct modulation of adipocyte metabolism. This CNS GLP-1 control of adipocyte lipid metabolism appears to be mediated at least in part by the sympathetic nervous system and is independent of parallel changes in food intake and body weight. Importantly, the CNS GLP-1 system loses the capacity to modulate adipocyte metabolism in obese states, suggesting an obesity-induced adipocyte resistance to CNS GLP-1.

Introduction

White adipose tissue (WAT) is key in the regulation of both glucose and lipid homeostasis, and adipocytes contain specific molecules and pathways that can rapidly switch between favoring lipid storage or lipid mobilization. These metabolic pathways confer a gatekeeper role on adipocytes in the regulation of lipid metabolism (Guilherme et al., 2008). Lipid excess, impaired lipid storage, and lipotoxicity contribute to obesity in part by fatty acids impacting on insulin signaling pathways. Thus, a functionally relevant dissection of molecular mechanisms directly regulating fatty acid deposition and mobilization is of considerable importance for the development of new therapeutics preventing and treating diabetes and obesity.

Glucagon-like peptide (GLP-1) is a gut hormone, neuropeptide and incretin (Baggio and Drucker, 2007), secreted in response to absorbed nutrients (Schirra et al., 1996). There is evidence that circulating GLP-1 receptor agonists can activate CNS neurons (Yamamoto et al., 2002) and that GLP-1 may cross the blood–brain barrier (Kastin et al., 2002). GLP-1 is also synthesized in specific neuron populations in the nucleus of the solitary tract of the hindbrain (Han et al., 1986; Jin et al., 1988), and GLP-1 receptors are found in many CNS areas known to be involved in the control of energy metabolism (Larsen et al., 1997a,b; Merchenthaler et al., 1999), including the hypothalamic arcuate and paraventricular nuclei. Consistent with this, GLP-1 has been reported to directly stimulate hypothalamic neuroendocrine neurons including those expressing pro-opiomelanocortin (Larsen et al., 1997b; Ma et al., 2007). Biologically, GLP-1 exerts a broad range of actions such as stimulating insulin release, reducing glucagon release, and reducing gastric emptying (Willms et al., 1996; Baggio et al., 2004), and at least some of its actions appear to be mediated through neuroendocrine mechanisms. CNS GLP-1 receptor activa-
tion has been linked to the control of food intake (Tang-Christensen et al., 1996; Turton et al., 1996; Pérez-Tilve et al., 2007), some stress responses (Kinzig et al., 2003), glucose homeostasis (Sandoval, 2008), and locomotor activity (Knauf et al., 2008). However, a potential role of CNS GLP-1 receptor activity in the direct control of lipid deposition or lipid mobilization remains unknown.

Specific circuits in the CNS have recently been found to be directly connected to WAT via the sympathetic nervous system (SNS), thereby providing an avenue for a direct CNS influence on adipocyte metabolism. This pathway may, therefore, provide the explanation as to how central administration of leptin (Buettner et al., 2008), ghrelin (Theander-Carrillo et al., 2006), neuropeptide Y (Zarjevski et al., 1994), and melanocortins (Nogueiras et al., 2007) control adipocyte metabolism. Because GLP-1 analogues are now approved and widely used as a therapeutic adjunct for human metabolic disease, we asked whether CNS GLP-1 action directly modulates peripheral lipid metabolism, and we demonstrate for the first time that CNS GLP-1 potently and rapidly decreases lipid deposition in WAT and liver. The actions on WAT, but not liver, are independent of changes in food intake and are partially modulated through the SNS. Interestingly, direct CNS GLP-1 modulation of peripheral lipid metabolism appears to be blunted in diet-induced obesity.

Materials and Methods

All procedures were approved either by the Institutional Animal Care and Use Committees at the University of Cincinnati and University of Iowa, in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, or the Vétérinaire Fédéral et Cantonal, Geneva, Switzerland.

Experiments. Several experiments were conducted, each of which was designed to answer a specific aspect of the overall hypothesis. At the termination of all of the experiments, the animals were killed by decapitation, trunk blood was collected, and several tissues were removed and stored at −80°C until further processing for the measurement of hormones, metabolites, and tissue-specific mRNA or protein expression of various enzymes.

In chronic experiments, Exendin 9–39 (7.5 nmol/d), an antagonist of the GLP-1 receptor, or GLP-1 (7–36) amide (0.75 nmol/d), both provided by Dr. R. Di Marchi (Indiana University, Bloomington, IN), were delivered via intracerebroventricular infusion for 7 or 48 h to mice. The doses used for Exendin 9–39 and GLP-1 were adapted from previous reports performed in rats showing that those doses were efficient in the doses used for Exendin 9–39 and GLP-1 were adapted from previous reports performed in rats showing that those doses were efficient. Mice were then infused with either saline, Exendin 9–39 (7.5 nmol/d), or GLP-1 (7–36) amide (0.75 nmol/d) for 7 or 48 h. After surgery, the animals received a single subcutaneous dose of 0.28 mg/kg buprenorphin (Buprenex; Reckitt Benckiser Healthcare). Because GLP-1 caused a marked suppression of food intake, a saline pair-fed group (restricted to the same amount of food each day as consumed by the intracerebroventricular GLP-1-infused mice) was also used.

The pair-feeding regimen consisted in giving one-third of the daily food amount in the morning and the remaining two-thirds just before onset of darkness. Thus, the experiments included three groups of animals: an ad libitum-fed control group infused with intracerebroventricular saline, an intracerebroventricular GLP-1-infused group, and a saline-pair-fed group.

Energy expenditure, locomotor activity, RQ, and lipid utilization. During intracerebroventricular treatment, mice were analyzed for 7 consecutive days for energy expenditure, RQ, and locomotor activity using a custom-made 32-cage calorimetry system (LabMaster; TSE Systems). The instrument consists of a combination of highly sensitive feeding and drinking sensors for automated online measurement. The calorimetry system is an open-circuit system that determines O2 consumption, CO2 production, and RQ (RQ = VCO2/V02). A photobeam-based activity-monitoring system detects and records every ambulatory movement including rearing and climbing movements in every cage. Detection of animal location is performed with infrared sensor pairs arranged in strips for horizontal and vertical (rearing) activity. The sensors for detection of movement operate efficiently in both light and dark phases allowing continuous recording. All of the parameters can be measured continuously and simultaneously in up to 32 animals. The mice (7–8 per group) were placed in the calorimetric system cages on day 1 of treatment. After 72 h of adaptation, data were collected over the subsequent 4 d.

Body composition was measured in mice infused intracerebroventricularly with saline or GLP-1 using nuclear magnetic resonance imaging (Whole Body Composition Analyzer; EchoMRI). Measurements were performed before surgery and before killing after 2 or 7 d of treatment.

Quantitative real-time-PCR procedure. Mice were killed by decapitation in the fed state (1 h after morning feeding), and several tissues were dissected, freeze-clamped, and stored at −80°C for subsequent measurement of mRNA expression of fatty acid synthase (FAS), stearoyl-CoA desaturase 1 (SCD-1), acyl-CoA:acyltransferase-1 (ACAT1), wooly protein lipase (LPL), carnitine palmitoyltransferase-1a (CPT-1a), hormone-sensitive lipase (HSL), β-adrenergic receptors 1, 2, and 3, and hypoxanthine guanine phosphoribosyltransferase (HPRT) by real-time (RT)-qPCR (Bio-Rad). See Table 1 for primer sequences. Total RNA was extracted from frozen tissue samples using TRIzol Reagent (Invitrogen). RNA integrity was assessed by performing a 1% agarose gel electrophoresis in 1X...
Table 1. Primer sequences used for real-time qPCR

| Gene      | Accession number | Forward sequence | Reverse sequence | PCR product | Annealing T° |
|-----------|------------------|------------------|------------------|-------------|--------------|
| ACCα      | NM13360          | 5′-GCC TCT TCC TGG CAA AGC AG-3′ | 5′-TGA CGG AAA CAT CTC TG-3′ | 239         | 60           |
| FAS       | NM007988         | 5′-TTG CTG GCA CTA CAG AAT GC-3′ | 5′-AAC AGC CCT AGA GGA AAT AT-3′ | 192         | 60           |
| SCD-1     | NM009127         | 5′-CTT CAA GGG CAG TTT GGC GG-3′ | 5′-CAA TGG TTT TCA TCA CGG TG-3′ | 203         | 60           |
| LPL       | NM008509         | 5′-CAC GAG GGC CTA ACT TCG AG-3′ | 5′-AAT CAC AGG GTC GCC TCT TG-3′ | 206         | 60           |
| CPT-1α    | AF017174         | 5′-GTC GCT TCT TCA AGG TCT GG-3′ | 5′-AAT AAA GAA GCA GCA GTC TG-3′ | 232         | 60           |
| HSL       | BC021642         | 5′-AGA ACA AGC CCA AGC GAT AC-3′ | 5′-ATC ACC TGC GAA GAA GCA C-3′ | 239         | 60           |
| SREBP1c   | NM011480         | 5′-TAG AGC ATA TCC CCC AGG TG-3′ | 5′-GGT ACC GGC CCC CAC AAC TA-3′ | 245         | 60           |
| β1-AR     | NM007419         | 5′-CG GCC TTT GTG GTG TTA AAT-3′ | 5′-GCA AGG GGA AAC ACT TCC TG-3′ | 232         | 60           |
| β2-AR     | NM007420         | 5′-GAC CAC AAA GCC CCT AAC AGC-3′ | 5′-GGT GAC GTA GCC CAA CAA GT-3′ | 153         | 60           |
| β3-AR     | NM013462         | 5′-GCC ACC TTC AAA TAA GTC CT-3′ | 5′-CCC ACT CCA CAC ACC TT-3′ | 220         | 60           |
| NOR-1     | NM015743         | 5′-TCA GCC TTT TTG GAG GCT TT-3′ | 5′-TAA CCC ATG TCC TCT GTC GA-3′ | 234         | 60           |
| HPRT      | NM135356         | 5′-TGC TGC AGA TGT CAT GAA GG-3′ | 5′-TAT GCC CCC CCG TGA TCA AT-3′ | 196         | 60           |

CNS GLP-1 reduces adiposity independent of food intake

Chronic intracerebroventricular infusion of GLP-1 (0.75 nmol/d for 7 d) decreased food intake in ad libitum-fed mice compared with intracerebroventricular saline-infused controls, whereas chronic intracerebroventricular infusion of Exendin 9–39 (7.5 nmol/d for 7 d) did not affect feeding behavior (Fig. 1A). A second control group of intracerebroventricular saline-infused animals was pair-fed to match the intake of GLP-1-infused mice (saline-pf). Weight gain of intracerebroventricular GLP-1-infused mice was significantly lower than that of controls or saline-pf mice (Fig. 1B), suggesting that the loss of body weight in GLP-1-infused mice is not entirely explained by the anorexigenic effect of GLP-1. Consistent with those data, central blockade of GLP-1 receptor by Exendin 9–39 increased the body weight (Fig. 1B), although Exendin 9–39-infused mice ate the same amount of food than the control group. The decreased body weight observed after intracerebroventricular GLP-1 infusion was correlated with a net loss of fat mass (Fig. 1C), which was not observed in the pair-fed control group. The increased body weight observed after intracerebroventricular Exendin 9–39 infusion, an antagonist for the GLP-1 receptor, was correlated with the gain of fat mass (Fig. 1D). Neither GLP-1 nor Exendin 9–39 changed the amount of nonfat mass (Fig. 1E).

Chronic intracerebroventricular GLP-1 infusion also prevented the expected compensatory decrease of energy expenditure which occurred in saline-pf mice (Fig. 1F–H), a phenomenon which could not be explained by changes in locomotor activity (Fig. 1I–K). Interestingly, however, continuous CNS GLP-1 infusion did result in a slight decrease of the RQ, particularly during the dark phase (Fig. 1L–N). These data indirectly suggest that central GLP-1 activation promotes a food intake independent shift of nutrient partitioning toward fat utilization, at the expense of lipid deposition rates.

These findings demonstrated that chronic central infusion of GLP-1 or Exendin 9–39 modified body weight and fat mass independent of food intake but did not exert any significant change on nonfat mass. Thus, our first data suggested that modulation of CNS GLP-1 receptor plays a relevant role in the regulation of adipocyte metabolism. However, the effects of GLP-1 on body weight were not consistent after 48 h, because CNS GLP-1-treated mice regained body weight at day 3 of infusion (Fig. 1C). Therefore, we decreased the time of the treatment. Constant intracerebroventricular GLP-1 infusion for 48 h induced markedly suppressed cumulative food intake (Fig. 2A) and reduced body weight (saline ad libitum, −0.11 ± 0.31 g; GLP-1, −4.14 ± 0.20 g; and saline-pf, −2.54 ± 0.46 g). Again, the loss of body weight in intracerebroventricular GLP-1-infused mice could not be sufficiently explained by its anorexigenic effects, as the saline-pf mice did not lose as much weight. Both intracerebroventricular GLP-1-infused and saline-pf mice exhibited less fat mass than the saline ad libitum group after treatment (Fig. 2B). This was demonstrated by the fact that at the end of the treatment, the amount of...
Fat mass present in both GLP-1-infused and saline-pf groups was too low to be detected by nuclear magnetic resonance, meaning that the loss of fat mass was higher in these two groups in comparison with the saline ad libitum group, in which the final amount of fat mass could be detected.

CNS GLP-1 levels determine white adipose tissue triglyceride metabolism

The greater decrease in fat mass in mice infused with intracerebroventricular GLP-1 for 48 h, relative to saline ad libitum and saline-pf mice, suggested direct stimulation of neural circuits that elicit TG mobilization from WAT by CNS GLP-1. To test this hypothesis, we first quantified TG lipid content in WAT and liver and observed that the total amount of TG/g in both tissues was decreased in response to chronic intracerebroventricular GLP-1 infusion (Fig. 2C,D). This phenomenon, however, was independent of food intake only for WAT (Fig. 2C), whereas in liver, this effect was predominantly associated with GLP-1’s anorectic actions as demonstrated by the fact that both GLP-1 and saline-pf groups exhibited the same levels of TG (Fig. 2D).

To begin to identify the molecular underpinnings responsible for the decreased TG content in WAT, we analyzed the lipid metabolism gene program. Independent of hypophagia, GLP-1 markedly decreased mRNA expression profiles of genes promoting lipogenesis, lipid deposition, and TG storage in adipocytes; i.e., these target genes included FAS, SCD-1, ACCα, and LPL (Fig. 2E). However, mRNA expression levels of enzymes promoting lipid mobilization or fat oxidation, including, for example, CPT-1α, were not significantly modified in mice infused with intracerebroventricular GLP-1 (Fig. 2E). In addition, sustained intracerebroventricular GLP-1 did not alter WAT mRNA expression of HSL, which, in its phosphorylated form, is considered a surrogate marker for lipid mobilization in WAT (Fig. 2F). To corroborate our gene expression findings, we quantified protein levels of FAS (Fig. 2F), which supported the conclusion of decreased lipid deposition-promoting programs in response to chronic intracerebroventricular infusion of GLP-1. Consistent with the observed lower hepatic TG content, intracerebroventricular GLP-1 markedly decreased mRNA levels of genes promoting lipogenesis and TG storage in liver. Interestingly and differing from effects in adipose tissue, that phenomenon seemed to be largely dependent on nutrient intake, as those hepatic gene programs were turned off to a similar extent in CNS saline-infused mice which were pair-fed to mice receiving intracerebroventricular GLP-1 (Fig. 2G).

No peripheral interference of centrally derived GLP-1 peptide

To rule out the possibility that centrally infused GLP-1 leaks out of the CNS into the circulation and elicits a response by directly acting at peripheral GLP-1 receptors, we administered GLP-1 peripherally (2 d, via subcutaneous minipumps) using the exact same dose as that infused centrally (0.75 nmol/d). There were no effects on food intake (Fig. 3A), body weight (Fig. 3B), or lipid metabolism in WAT (Fig. 3C) after peripheral infusion of GLP-1. We, therefore, conclude that the effects observed during intracerebroventricular administration are attributable to CNS GLP-1-R activation.

Impact of sustained intracerebroventricular GLP-1 on adipocyte metabolism is blunted in diet-induced obese mice

To determine whether the effect of intracerebroventricular GLP-1 would be sustained in an obese animal model, we used
diet-induced obesity (DIO) C57B6/6J mice (mean of 49.5 g body weight), a well established mouse obesity model. Mice received intracerebroventricular GLP-1 (0.75 nmol/d) or saline for 48 h. Consistent with data obtained in lean mice, DIO mice responded to intracerebroventricular GLP-1 with a decrease in food intake (Fig. 4A) and a reduction of body weight (saline *ad libitum*, −2.35 ± 0.31 g; GLP-1, −4.91 ± 0.38 g; and saline-pf, −3.27 ± 0.28 g). Interestingly, the reduction of body weight was not reflected by a respective decrease in fat mass in DIO mice (Fig. 4B). Consistent with the lack of changes in adiposity, we failed to detect changes in any of the previously described gene expression program of lipid metabolism in this obesity model (Fig. 4C). Thus, we conclude that the regulatory impact of CNS GLP-1-R signaling on food intake and body weight is preserved in DIO mice, although these mice become resistant to a direct CNS GLP-1 control over WAT lipid metabolism.

**Role of the sympathetic nervous system in the CNS GLP-1 control of lipid metabolism**

Adipocytes are connected with hypothalamic areas controlling energy balance via the autonomic nervous system, in particular the SNS. To determine whether CNS GLP-1 activity directly triggers the efferent SNS projections to WAT, we used multifiber recording to test the effect of CNS GLP-1-R activation on SNS nerve subserving WAT. We found that CNS GLP-1-R activation via intracerebroventricular injection of low dose GLP-1 increased SNA recorded from nerve endings in epididymal WAT (Fig. 5A–C). This effect was dose-dependent and had a relatively slow onset, suggesting that gene expression changes within some brain cells might be involved downstream of GLP-1-R activation and upstream of CNS SNS efferents. The WAT SNS activity started to increase 30–60 min after the start of intracerebroventricular GLP-1 infusion and reached a maximum at ~150 min (Fig. 5B, C).

We next tested the physiological relevance of GLP-1 activation of SNA by examining whether CNS GLP-1-R activation would affect WAT lipid metabolism in the absence of SNS signaling. For this purpose, we treated wt and triple (β1-, β2-, and β3-) AR-deficient mice (TKO) with intracerebroventricular GLP-1 using the same treatment paradigm (0.75 nmol/d, 48 h). Intracerebroventricular GLP-1 decreased cumulative food intake in wt mice as well as in TKO mice (Fig. 6A). Body weight of wt mice was also reduced by intracerebroventricular GLP-1, whereas TKO mice, although not significant, showed a similar profile in the decrease of body weight (Fig. 6B). The WAT TG synthesis pathways were markedly downregulated in response to intracerebroventricular GLP-1 in wt mice as reflected by decreased mRNA levels of FAS (Fig. 6C), SCD-1 (Fig. 6D), and ACCα (Fig. 6E), whereas those effects were not observed in TKO mice (Fig. 6C–E). These findings indicate an important mediating role for the SNS in the CNS control of lipid metabolism. We also corroborated that protein levels of FAS were correlated with its gene expression, consistent with our previous findings (Fig. 6F). Contrary to the specific and direct actions of intracerebroventricular GLP-1 on WAT of wt mice but not TKO mice, we observed that in liver of both wt and TKO mice the expression of lipid synthesis and deposition-promoting enzymes was decreased in response to intracerebroventricular GLP-1 (supplemental Fig. 1, available at www.jneurosci.org as supplemental material). Therefore, our results suggest that deficient SNS signaling specifically affects the direct CNS GLP-1-mediated control over adipocyte metabolism.

Finally, we assessed if and to what extent sustained CNS
GLP-1 infusion would modulate the SNS effectors in WAT. H9252-ARs are a family of G-protein-coupled receptors that represent a key link involved in the regulation of adipocyte lipid metabolism by the SNS (van Baak, 2001; Bartness and Song, 2007). Therefore, we measured mRNA expression of beta1, 2, and 3 adrenergic receptors (beta1-AR, beta2-AR, beta3-AR) in WAT of intracerebroventricular GLP-1-infused lean and obese mice. The gene expression of beta1-AR was slightly increased (Fig. 7A), and beta2-AR mRNA expression levels were markedly stimulated in WAT in response to CNS GLP-1 of lean mice (Fig. 7B). No changes were observed in beta3-AR gene expression (Fig. 7C). Intriguingly and consistent with our main hypothesis, we failed to detect any significant changes in receptor expression patterns in the WAT of DIO mice receiving intracerebroventricular GLP-1 (Fig. 7E–G).

We next assessed the specific gene expression of the nuclear receptor NOR-1, a specific target of the beta adrenergic signal (Pearen et al., 2006) as a potential downstream effector of SNS activity in WAT (supplemental Fig. 2, available at www.jneurosci.org as supplemental material), and measured its levels in WAT of lean and obese mice (Fig. 7). NOR-1 mRNA expression was increased in WAT of lean mice when compared with saline-ad libitum and saline-pf mice in response to continued CNS GLP-1 (Fig. 7D). On the contrary, NOR-1 gene expression was unmodified in the WAT of DIO mice, consistent with a potentially important functional role of NOR-1 in intracellular metabolic processes (Fig. 7H).

Sustained CNS GLP-1 infusion did not change plasma levels

Figure 3. A–C. Effect of a 2 d peripheral GLP-1 (0.75 nmol/d) infusion on cumulative food intake (A), body weight change (B), and WAT mRNA expression of FAS, SCD-1, ACCae, LPL, and CPT-1α (C). Data are presented as values normalized to HRPT, which was used as a housekeeping gene. mRNA levels are relative to controls. Values are mean ± SEM of 7–8 animals per group.

Figure 4. A–C. Effect of a 2 d intracerebroventricular GLP-1 (0.75 nmol/d) infusion in DIO mice on cumulative food intake (A), fat mass change (B), and WAT mRNA expression of FAS, SCD-1, ACCae, and CPT-1α (C). Data are presented as values normalized to HRPT, which was used as a housekeeping gene. mRNA levels are relative to controls. Values are mean ± SEM of 7–8 animals per group. *p < 0.01 versus saline.
of insulin, glucagon or TG (Table 2). Plasma leptin levels were significantly decreased by CNS GLP-1 treatment in wt mice as expected but did not change in TKO GLP-1-infused mice (Table 2). Plasma total GLP-1 levels were elevated both in CNS GLP-1-infused wt and TKO mice (Table 2).

Discussion

We report herein that the CNS GLP-1 system directly controls adipocyte lipid metabolism. Our central finding is that when GLP-1 is administered into the CNS at a slow infusion rate via an osmotic minipump, it potently decreases lipid deposition in adipocytes of lean but not obese mice. These actions seem to be partially modulated through effects on sympathetic outflow, and more specifically by β1- and β2-AR, thereby efficiently shifting substrate metabolism to reduce energy storage and adiposity. These findings provide a compelling explanation for how fat mass decreases in response to an increase of CNS GLP-1 activity independent of its anorexigenic actions.

Central GLP-1 signaling reduces food intake (Turton et al., 1996) as well as mediating aspects of visceral illness (Seeley et al., 2000) and stress (Yamamoto et al., 2002; Kinzig et al., 2003). More recent reports indicate that GLP-1, acting on its receptors in the brain, is linked to the control of peripheral glucose homeostasis by inhibiting noninsulin-mediated glucose uptake by muscle and increasing insulin secretion from the pancreas (Knauf et al., 2005; Sandoval, 2008). Hence, one of the functional roles of the CNS GLP-1 system appears to be to modulate activity in peripheral organs that are crucial for the maintenance of energy homeostasis. In view of our present findings in mice, we conclude that another of those peripheral organs is the WAT.

The present experiments have confirmed that activation of the CNS GLP-1 system can decrease food intake and body weight (Tang-Christensen et al., 1996, 1998; Meeran et al., 1999; Rodriguez de Fonseca et al., 2000). The decrease in body weight is consistent with the observed lower amount of fat mass after central GLP-1 infusion. Most importantly, the decreased fat mass in mice receiving chronic intracerebroventricular GLP-1, in comparison with levels in saline ad libitum and saline-pf mice, led us to investigate the molecular pathways mediating CNS GLP-1 actions in WAT. We found that pharmacological stimulation of the CNS GLP-1 system decreased WAT TG content and deposition independent of its anorexigenic actions. However, in contrast to WAT, the effects of CNS GLP-1 on hepatic lipid deposition are dependent on and presumably secondary to reduced nutrient intake. Although GLP-1-R has not been found in WAT (Bullock et al., 1996), several studies have suggested that GLP-1 can directly act on adipocyte metabolism, although the molecular mechanisms modulating those peripheral actions are unknown (Ruiz-Grande et al., 1992; Mérida et al., 1993; Valverde et al., 1993; Bertin et al., 2001; Villanueva-Peñacarrillo et al., 2001; Sanchez et al., 2005, 2006). We have excluded the possibility that increased peripheral GLP-1 levels contributed to the observed effects, because peripheral infusion of the identical amount of GLP-1 failed to trigger any effects. Nonetheless, we did detect a slight increase of plasma total GLP-1 levels after central GLP-1 infusion. The reason for the increase is unclear, but parallel occurrences have been reported. Central infusion of ghrelin elicits increased plasma ghrelin levels (Theander-Carrillo et al., 2006), and central administration of insulin leads to a transient increase of pancreatic insulin secretion (Woods et al., 1998). In the case of GLP-1, the present findings cannot be explained by increased peripheral GLP-1 levels, because peripheral infusion of amounts identical to those administered centrally failed to exert any effects. To our knowledge, this is the first report documenting the potential effects of CNS GLP-1 on adipocyte lipid metabolism.

Available data from DIO rodents, which may represent the form of obesity encountered in most obese humans, strongly suggest that central resistance to some hormones regulating food intake plays a significant role in the development and progression of the disease. The mechanisms by which these hormones act are not yet fully understood, but some data suggest that the hypothalamic-pituitary-adrenal axis may play a role in the development of obesity (Simpson et al., 1999). In addition, some recent studies have suggested that the release of endogenous glucagon-like peptides may be increased in obese humans (Pellin et al., 1997; Righi et al., 1998; Silverstone et al., 1998; King et al., 1999; Heymsfield et al., 2000). Some of these peptides, such as GLP-1, are known to decrease food intake and body weight (Tuck et al., 1995; Turton et al., 1996). However, the mechanisms by which these hormones act in the hypothalamus are not yet fully understood, and more research is needed to clarify the role of the hypothalamic-pituitary-adrenal axis in the development of obesity.
intake contribute to the development of obesity (Howard et al., 2004; Myers et al., 2008). The most extensively studied hormone in this regard is leptin, whose central anorectic action is reduced in DIO rats (Widdowson et al., 1997) and DIO mice (Lin et al., 2000; Howard et al., 2004; Myers et al., 2008). It is, therefore, reasonable to hypothesize that other central signaling pathways implicated in energy homeostasis might be defective in obese states. Perhaps consistent with this, a recent report indicates that chronic blockage of brain GLP-1 signaling by Exendin-9 totally prevents hyperinsulinemia and insulin-resistance in DIO mice (Knauf et al., 2008), suggesting that the central GLP-1 actions on glucose homeostasis are unaltered in obese models. In the present experiments, we evaluated if pharmacological stimulation of specific receptor mediating CNS GLP-1 actions on WAT. We found that intracerebroventricular GLP-1 infusion increases the gene expression of β1-AR and especially β2-AR in WAT of lean mice but not in DIO mice. The lack of changes of β-AR gene expression in the WAT of obese mice is in agreement with previous reports demonstrating a decreased sensitivity of fat cells to adrenergic stimulation in obesity (van Baak, 2001). Although an additional role of classic hypothalamus–pituitary–endocrine mechanisms cannot be entirely ruled out, our combined set of data on SNA activity, genetically engineered β-adrenergic receptor deficient mice, and β-ARs gene expression profiles indicate that the SNS plays a functionally important role in the observed CNS GLP-1–WAT cross talk.

CNS GLP-1–R would be also efficient on adipocyte metabolism in DIO mice. Centrally infused GLP-1 in DIO mice elicited suppression of food intake and reduced body weight gain relative to results in saline ad libitum and saline-pf mice. However, the loss of body weight was not correlated with the amount fat mass, which remained unchanged in DIO mice with chronic intracerebroventricular GLP-1. Consistent with the lack of effects of CNS GLP-1 on fat mass, we also failed to detect any significant change in the expression of several key enzymes regulating lipid metabolism in WAT. Therefore, we conclude that obesity is associated with a selective central GLP-1-resistance: the CNS GLP-1 system is efficiently regulating food intake, body weight, and glucose homeostasis (Knauf et al., 2008), but it has no capacity to exert its actions on adipocyte metabolism.

To dissect the molecular underpinnings responsible for actions of CNS GLP-1 on WAT of lean but not obese mice, we analyzed the role of the SNS. The SNS connects WAT cells via a direct neuronal circuit with homeostatic control areas in the CNS (van Baak, 2001). We, therefore, tested the hypothesis that the SNS system may be responsible for informing adipocytes about changes in CNS GLP-1 tone. For this purpose, we have performed direct recording of SNA combined with experiments in genetically manipulated mice lacking β-adrenergic receptors. Our findings demonstrate that CNS GLP-1 increases SNS activity to epididymal WAT. However, it is important to point out that the increased SNA or even the WAT lipid metabolism changes could theoretically be secondary to endocrine changes in the hypothalamus-pituitary-adrenal axis and/or the hypothalamus-pituitary-thyroid axis. Moreover, we acknowledge that complete disruption of SNS signaling in the TKO mice may create undesired tangential phenotypes that could have interfered with our interpretation of the neuropharmacology studies in this loss-of-function model.

However, we also assessed the expression of specific receptor mediating CNS GLP-1 actions on WAT. We found that intracerebroventricular GLP-1 infusion increases the gene expression of β1-AR and especially β2-AR in WAT of lean mice but not in DIO mice. The lack of changes of β-AR gene expression in the WAT of obese mice is in agreement with previous reports demonstrating a decreased sensitivity of fat cells to adrenergic stimulation in obesity (van Baak, 2001). Although an additional role of classic hypothalamus–pituitary–endocrine mechanisms cannot be entirely ruled out, our combined set of data on SNA activity, genetically engineered β-adrenergic receptor deficient mice, and β-ARs gene expression profiles indicate that the SNS plays a functionally important role in the observed CNS GLP-1–WAT cross talk.

Table 2. Plasma levels of insulin, leptin, GLP-1, and glucagon in wt and TKO mice treated intracerebroventricularly with either GLP-1 (0.75 nmol/d) or vehicle (saline) for 48 h

|           | wt          |         | TKO         |         |
|-----------|-------------|---------|-------------|---------|
|           | Saline      | GLP-1   | Saline      | GLP-1   |
| Insulin   | 0.63 ± 0.14 | 0.33 ± 0.03 | 0.58 ± 0.24 | 0.51 ± 0.08 |
| Leptin    | 1.88 ± 0.45 | 0.92 ± 0.13* | 1.75 ± 0.26 | 2.53 ± 0.83 |
| GLP-1 (ng/ml) (total) | 0.21 ± 0.03 | 14.41 ± 7.62* | 0.08 ± 0.01 | 13.72 ± 6.30* |
| Glucagon (ng/ml) | 0.11 ± 0.02 | 0.15 ± 0.05 | 0.07 ± 0.02 | 0.07 ± 0.02 |
| TG (mg/ml) | 2.9 ± 0.08 | 2.54 ± 0.15 | 3.07 ± 0.24 | 2.27 ± 0.12 |

Values are means ± SEM, n = 6–7 mice per group.

*p < 0.05 versus saline.
Finally, it has been reported that NOR-1, a specific target of β2-AR, is involved in the regulation of genes controlling fatty acid and glucose oxidation in skeletal muscle (Pearen et al., 2006, 2008). As NOR-1 has also been identified in adipose tissue, we hypothesized that NOR-1 might be regulated by the increased expression of β2-AR in WAT of centrally GLP-1-infused lean mice. Our finding of an increase in NOR-1 expression in WAT of lean but not obese mice supports the hypothesis that NOR-1 is positively regulated by β2-AR and plays an important role in fatty acid metabolism not only in muscle but also in WAT.

As summarized in Figure 8, we have provided a combination of pharmacological and genetic evidence to demonstrate that the CNS GLP-1 system decreases fat storage via direct modulation of adipocyte metabolism. This CNS GLP-1 control of adipocyte lipid metabolism appears to be, at least to a significant extent, mediated by the SNS, particularly β2-AR, and is independent of parallel changes in food intake and body weight. Importantly, the CNS GLP-1 system loses the capacity to modulate adipocyte metabolism in obese states, suggesting an obesity-induced adipocyte resistance to CNS GLP-1.

References

Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157.

Baggio LL, Huang Q, Brown TJ, Drucker DJ (2004) A recombinant human glucagon-like peptide (GLP-1)-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53:2492–2500.

Bartness TJ, Song CK (2007) Thematic review series: adipocyte biology. Sympathetic and sensory innervation of white adipose tissue. J Lipid Res 48:1655–1672.

Bertin E, Arner P, Bolinder J, Hagström-Toft E (2001) Action of glucagon and glucagon-like peptide-1 (7–36) amidine on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J Clin Endocrinol Metab 86:1229–1234.

Buettner C, Muse ED, Cheng A, Chen L, Scherer T, Pocai A, Li X, Harvey-White J, Schwartz GJ, Kunos G, Rossetti L, Buettner C (2008) Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med 14:667–675.

Bullock BP, Heller RS, Habener JF (1996) Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137:2968–2978.

Guilherme A, Virbasius JV, Puri V, Czech MP (2008) Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9:367–377.

Han VK, Hynes MA, Jin C, Towlle AC, Luder JM, Lund PK (1986) Cellular localization of proglucagon/glucagon-like peptide I messenger RNAs in rat brain. J Neurosci Res 16:97–107.

Howard JK, Cave BJ, Oksanen LJ, Tzameli I, Björbaek C, Flier JS (2004) Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med 10:734–738.

Jin SL, Han VK, Simmons JG, Towlle AC, Luder JM, Lund PK (1988) Distribution of glucagon-like peptide I (GLP-1), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 271:519–532.

Kastin AJ, Akerstrom V, Pan W (2002) Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 18:17–14.

Kinzig KP, D’Alessio DA, Herman JP, Sakai RR, Vahl TP, Figueiredo HF, Murphy EK, Seeley RJ, Figueiredo HF (2003) CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 23:6163–6170.

Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, Benhamed F, Grémeaux T, Drucker DJ, Kahn CR, Girard J, Tanti JF, Delzenne NM, Pestic C, Burcelin R (2005) Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115:3534–3536.

Knauf C, Cani PD, Alt-Belghaoui A, Benani A, Dray C, Cabou C, Colom A, Uldry M, Rastrelli S, Sabatier E, Godet N, Waget N, Pénicaud L, Valet P, Burcelin R (2008) Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 149:4768–4777.

Larsen PJ, Tang-Christensen M, Holst JI, Orskov C (1997a) Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77:257–270.
Larsen PJ, Tang-Christensen M, Jessop DS (1997b) Central administration of glucagon-like peptide 1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138:4445–4455.

Lin S, Thomas TC, Storlien LH, Huang XF (2000) Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int J Obes Relat Metab Disord 24:639–646.

López M, Lage R, Saha AK, Pérez-Tilve D, Vázquez MJ, Varela L, Sangiao-Alvarelos S, Tovar S, Raghay K, Rodriguez-Cuenca S, Deodireva RM, Castañeda T, Datta R, Dong JZ, Culler M, Sleeman MW, Alvarez CV, Gallego R, Lelliott CJ, Carlning D, et al. (2008) Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab 7:389–399.

Ma X, Brunning J, Ashcroft FM (2007) Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J Neurosci 27:7125–7129.

Meeran K, O’Shea D, Edwards CM, Turton MD, Heath MM, Gunn I, Abbasana S, Rossi M, Small CJ, Goldstone AP, Taylor GM, Sunter D, Steere J, Choi SJ, Ghatel MA, Bloom SR (1999) Repeated intracerebroventricular administration of glucagon-like peptide 1(7–36) amide or Exendin (9–39) alters body weight in the rat. Endocrinology 140:244–250.

Menchenthaler I, Lane M, Shughrue P (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403:261–280.

Mérida E, Delgado E, Molina LM, Villanueva-Penacarrillo ML, Valverde I (1993) Presence of glucagon and glucagon-like peptide-1(7–36)amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab 77:1654–1667.

Myers MG, Cowley MA, Münzberg H (2008) Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 70:537–556.

Nogueiras R, Wiedmer P, Perez-Tilve D, Veyrat-Durebex C, Keogh JM, Sutton GM, Pfluger PT, Castaneda TR, Neschen S, Hofmann SM, Howlens PN, Morgan DA, Benoit SC, Szanto I, Schrumpf A, Joost HG, Hammond C, Hui DY, Woods SC, et al. (2007) The central melanocortin system directly controls peripheral lipid metabolism. J Clin Invest 117:3475–3488.

Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschop J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, Fekete C, Reizes O, Rohner-Jeanrenaud F, Tschop MH (2008) Peripheral, but not central, CB1 antagonism provides food intake independent metabolic benefits in diet-induced obese rats. Diabetes 57:2977–2991.

Pearen MA, Ryall JG, Maxwell MA, Ohkura N, Lynch GS, Muscat GE (2006) The orphan nuclear receptor, NOR-1, is a target of beta-adrenergic signaling in skeletal muscle. Endocrinology 147:5217–5227.

Pearen MA, Myers SA, Raichur S, Ryall JG, Lynch GS, Muscat GE (2008) The orphan nuclear receptor, NOR-1, a target of beta-adrenergic signaling, regulates gene expression that controls oxidative metabolism in skeletal muscle. Endocrinology 149:2853–2865.

Pérez-Tilve D, González-Martías L, Alvarez-Crespo M, Leiras R, Tovar S, Díéguez C, Mallo F (2007) Exendin-4 potently decreases ghrelin levels in euglycemic and hyperglycemic rats. J Clin Invest 118:1458–1467.

Rodriguez de Fonseca F, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O, Gómez R, Muñoz RM, Eng J, Blázquez E (2000) Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49:709–717.

Ruíz-Grande C, Alarcón C, Mérida E, Valverde I (1992) Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Peptides 13:13–16.

Sancho V, Trigo MV, González N, Valverde I, Malaisse WJ, Villanueva-Péncarillo ML (2005) Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J Mol Endocrinol 35:27–38.

Sheffield VC (2008) Leptin resistance contributes to obesity and hyperglycemia in humans. J Clin Invest 97:92–103.

Seno RJ, Blake K, Rushing PA, Benoit S, Eng J, Woods SC, D’Alessio D (2000) The role of CNS glucagon-like peptide-1(7–36)amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 20:1616–1621.

Tang-Christensen M, Larsen PJ, Gøke R, Fink-Jensen A, Jessop DS, Møller M, Sheikh SP (1996) Central administration of GLP-1(7–36)amide inhibits food and water intake in rats. Am J Physiol 271:R848–856.

Tang-Christensen M, Vrang N, Larsen PJ (1998) Glucagon-like peptide 1(7–36)amide’s central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 47:530–537.

Theander-Carrillo C, Wiedmer P, Cettour-Rose P, Nogueiras R, Perez-Tilve D, Pfluger PT, Castaneda TR, Muzzin P, Schrumpf A, Szanto I, Tschop MH, Rohner-Jeanrenaud F (2006) Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 116:1983–1993.

Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatel MA, Herbert J, Bloom SR (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69–72.

Valverde I, Mérida E, Delgado E, Trapote MA, Villanueva-Péncarillo ML (1993) Presence and characterization of glucagon-like peptide-1(7–36)amide receptors in solubilized membranes of rat adipose tissue. Endocrinology 132:75–79.

van Baak MA (2001) The peripheral sympathetic nervous system in human obesity. Obes Rev 2:3–14.

Vázquez MJ, González CR, Varela L, Lage R, Tovar S, Sangiao-Alvarelos S, Williams LM, Vidal-Puig A, Nogueiras R, López M, Díéguez C (2008) Central resistin regulates hypothalamic and peripheral lipid metabolism in a nutritional-dependent fashion. Endocrinology 149:4534–4543.

Villanueva-Péncarillo ML, Márquez L, González N, Díaz-Miguel M, Valverde I (2001) Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res 33:73–77.

Widdowson PS, Upton R, Buckingham RA, Arch J, Williams G (1997) Inhibition of food response to intracerebroventricular injection of leptin is attenuated in rats with diet-induced obesity. Diabetes 46:1782–1785.

Williams B, Wernher J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA (1996) Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1) in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327–332.

Woods SC, Seeley RJ, Porte D Jr, Schwartz MW (1998) Signals that regulate food intake and energy homeostasis. Science 280:1378–1383.

Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK (2002) Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110:43–52.

Zarjeski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B (1994) Intracerebroventricular administration of neuropeptide Y to normal rats has divergent effects on glucose utilization by adipose tissue and skeletal muscle. Diabetes 43:764–769.